WB result of FCRL5 Recombinant Rabbit mAb
Primary antibody: FCRL5 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: K-562 transfected with FCRL5-Luc fusion protein whole cell lysate 20 µg
Lane 2: K-562 transfected with FCRL2-Luc fusion protein whole cell lysate 20 µg
Lane 3: K-562 transfected with FCRL3-Luc fusion protein whole cell lysate 20 µg
Lane 4: K-562 transfected with empty vector whole cell lysate 20 µg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 106 kDa
Observed MW: 100-160 kDa
This blot was developed with high sensitivity substrate
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | FCRL5 |
| Synonyms | Fc receptor-like protein 5; FcR-like protein 5; FcRL5; BXMAS1; Fc receptor homolog 5 (FcRH5); Immune receptor translocation-associated protein 2; CD307e; FCRH5; IRTA2 |
| Immunogen | Recombinant Protein |
| Location | Cell membrane |
| Accession | Q96RD9 |
| Clone Number | S-3854-2 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB, IHC-P |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:500-1:1000 | Hu |
| IHC-P | 1:200 | Hu |
Background
FCRL5 (Fc receptor-like protein 5, also known as FcRH5 or IRTA2) is a type I transmembrane glycoprotein with B-cell lineage-restricted expression, belonging to the Fc receptor-like family. Its extracellular region contains nine immunoglobulin-like domains (D1–D9), while its intracellular tail encodes both two classical ITIM motifs and one ITAM-like motif. FCRL5 is mainly expressed on the surface of naive B cells, memory B cells, and plasma cells, and functions as a co-receptor of the BCR with bidirectional regulatory activity: upon co-crosslinking with the BCR, its ITIMs mediate recruitment of the SHP-1 phosphatase, suppressing calcium flux and B-cell activation. A cryo-electron microscopy structural study published in Science Advances in 2026 revealed that human FCRL5 recognizes IgG in a unique avidity-dependent "1:2" mode—the D1–D2 domains bind the first Fc molecule, while the D3 domain binds a spatially adjacent second Fc molecule—thereby specifically recognizing densely arrayed IgG within immune complexes rather than monomeric IgG, and can mediate internalization of IgG immune complexes. At the pathological level, FCRL5 is almost universally highly expressed in multiple myeloma and participates in the transformation of the CD24⁻FCRL5⁺ B-cell subset into malignant plasma cells by interacting with the IRF4/SPI1 complex to promote differentiation. On this basis, therapeutic strategies targeting FCRL5—such as CAR-T cells, bispecific T-cell engagers (e.g., cevostamab), and BCMA/FCRL5 trispecific antibodies—are being actively advanced in clinical or preclinical studies.
Picture
Picture
Western Blot
Immunohistochemistry
IHC shows positive staining in paraffin-embedded human diffuse large B-cell lymphoma. Anti-FCRL5 antibody was used at 1/200 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.
